Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders and certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
Website: ligand.com



Growth: Bad revenue growth rate -44.0%, there is slowdown compared to average historical growth rates 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +25.2%. On average the margin is improving unsteadily. Gross margin is high, +94.1%. In the last quarter the company beat the estimated EPS, +156.2%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.63 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 56.1% higher than minimum and 29.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.1x by EV / Sales multiple , the company can be 74.5% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.012% of cap.)

Key Financials (Download financials)

Ticker: LGND
Share price, USD:  (-8.1%)72.52
year average price 68.67  


year start price 76.77 2023-04-20

min close price 49.57 2023-10-27

max close price 89.20 2024-02-27

current price 72.52 2024-04-19
Common stocks: 16 861 299

Dividend Yield:  0.0%
FCF Yield LTM: 3.3%
EV / LTM EBITDA: 32.1x
EV / EBITDA annualized: 33.1x
Last revenue growth (y/y):  -44.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  35.3%
EV / Sales: 8.1x
Margin (EBITDA LTM / Revenue): 25.2%
Fundamental value created in LTM:
Market Cap ($m): 1 223
Net Debt ($m): -164
EV (Enterprise Value): 1 059
Price to Book: 1.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-17Zacks Investment Research

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

2024-04-05Zacks Investment Research

Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts

2024-04-04Zacks Investment Research

Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It?

2024-04-04Zacks Investment Research

Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know

2024-04-01Zacks Investment Research

Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note

2024-03-26Zacks Investment Research

Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know

2024-03-21Zacks Investment Research

Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock

2024-03-20Zacks Investment Research

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

2024-03-19Zacks Investment Research

Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?

2024-03-14Zacks Investment Research

Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2024-02-29 2023-11-09 2023-08-09 2023-05-08 2023-02-28 2022-11-08
acceptedDate 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 28M 33M 26M 44M 50M 66M
costOfRevenue 2M 3M 2M 4M 22M 14M
grossProfit 26M 29M 25M 40M 29M 52M
grossProfitRatio 0.941 0.894 0.937 0.915 0.571 0.786
researchAndDevelopmentExpenses 5M 6M 7M 7M 9M 22M
generalAndAdministrativeExpenses 16M 15M 11M 11M 31M 17M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 16M 15M 11M 11M 31M 17M
otherExpenses -8M -4M -873 000 9M 9M 12M
operatingExpenses 30M 28M 27M 26M 49M 51M
costAndExpenses 31M 32M 28M 30M 70M 65M
interestIncome 2M 2M 2M 1M 1023.000 259 000
interestExpense 131 000 -1000.000 2M 1M 571.741 332 000
depreciationAndAmortization 9M 8M 9M -31M -36M 12M
ebitda 10M 23M 3M -17M -56M 13M
ebitdaratio 0.351 0.714 0.097 -0.382 -1.108 0.202
operatingIncome -3M -122 000 -2M 14M -20M 2M
operatingIncomeRatio -0.119 -0.004 -0.075 0.323 -0.399 0.024
totalOtherIncomeExpensesNet 20M -19M 3M 41M 44M -702 000
incomeBeforeTax 17M -15M 3M 56M 24M 857 000
incomeBeforeTaxRatio 0.608 -0.467 0.120 1.263 0.479 0.013
incomeTaxExpense -1M -3M 881 000 12M 39M 453 000
netIncome 18M -13M 2M 42M -15M 404 000
netIncomeRatio 0.647 -0.389 0.087 0.954 -0.288 0.006
eps 1.040 -0.740 0.130 2.460 -0.860 0.020
epsdiluted 1.030 -0.740 0.130 2.330 -0.860 0.020
weightedAverageShsOut 17M 17M 18M 17M 17M 17M
weightedAverageShsOutDil 18M 17M 18M 18M 17M 17M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2024-02-29 2023-11-09 2023-08-09 2023-05-08 2023-02-28 2022-11-08
acceptedDate 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 23M 19M 219M 283M 45 006 4M
shortTermInvestments 147M 171M 191M 194M 166 864 117M
cashAndShortTermInvestments 170M 191M 219M 283M 212M 121M
netReceivables 39M 39M 28M 29M 35M 66M
inventory 24M 25M 27M 14M 13M 22M
otherCurrentAssets 4M 3M 3M 2M 3M 11M
totalCurrentAssets 237M 258M 277M 328M 264M 220M
propertyPlantEquipmentNet 9M 10M 15M 16M 15M 47M
goodwill 103M 419M 431M 440M 448M 698M
intangibleAssets 367M 7M 11M 10M 10M 10M
goodwillAndIntangibleAssets 470M 425M 442M 450M 458M 708M
longTermInvestments 48M 47M 0 0 0 0
taxAssets 46M 9M 9M 875 000 9M 36M
otherNonCurrentAssets 22M 21M 16M 16M 17M 40M
totalNonCurrentAssets 596M 511M 481M 483M 499M 830M
otherAssets 0 0 0 0 0 0
totalAssets 833M 769M 758M 811M 763M 1 051M
accountPayables 15M 13M 17M 6M 5307.000 35M
shortTermDebt 410 000 497 000 680 000 77M 77M 79M
taxPayables 0 4M 11M 0 0 10M
deferredRevenue 1M 4M 11M 257 000 355 000 10M
otherCurrentLiabilities 256 000 916 000 448 000 15M 21M 11M
totalCurrentLiabilities 17M 19M 29M 99M 99M 135M
longTermDebt 6M 6M 11M 11M 10M 35M
deferredRevenueNonCurrent 15M 0 0 0 31M 6M
deferredTaxLiabilitiesNonCurrent 77M 32M 28M 30M 31M 30M
otherNonCurrentLiabilities 16M 47M 25M 25M -5M -25M
totalNonCurrentLiabilities 114M 85M 64M 66M 66M 99M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 6M 6M 12M 12M 11M 2M
totalLiabilities 131M 104M 93M 165M 165M 234M
preferredStock 0 0 0 0 0 0
commonStock 18 000 18 000 17 000 17 000 17.000 17 000
retainedEarnings 503M 485M 495M 493M 450 862 468M
accumulatedOtherComprehensiveIncomeLoss -817 000 -944 000 -967 000 -935 000 -984.000 -1M
othertotalStockholdersEquity 199M 182M 171M 154M 597M 349M
totalStockholdersEquity 701M 665M 665M 646M 597M 816M
totalEquity 701M 665M 665M 646M 597M 816M
totalLiabilitiesAndStockholdersEquity 833M 769M 758M 811M 763M 1 051M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 833M 769M 758M 811M 763M 1 051M
totalInvestments 196M 204M 191M 194M 166 864 117M
totalDebt 6M 6M 12M 89M 88M 79M
netDebt -17M -13M -207M -194M 88M 75M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2024-02-29 2023-11-09 2023-08-09 2023-05-08 2023-02-28 2022-11-08
acceptedDate 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 18M -10M 2M 42M -17M 404 000
depreciationAndAmortization 9M 9M 9M 9M 11M 14M
deferredIncomeTax 5M 8M -10M 9M 46M -13M
stockBasedCompensation 6M 7M 7M 6M 29M 13M
changeInWorkingCapital -16M -21M -5M 8M 27M 5M
accountsReceivables 3M -8M 1M 1M 35M -3M
inventory 707 000 -611 000 -13M 2M 1M 962 000
accountsPayables 2M -2M -5M -435 000 -3M 0
otherWorkingCapital -21M -11M 11M 5M -6M 7M
otherNonCashItems -14M 15M -3M -40M -42M 2M
netCashProvidedByOperatingActivities 8M 8M -82 000 34M 53M 20M
investmentsInPropertyPlantAndEquipment -51M -487 000 -203 000 -2M -1M -5M
acquisitionsNet -14 000 -26M 0 0 0 0
purchasesOfInvestments -20M -18M -49M -40M -12M -580 000
salesMaturitiesOfInvestments 60M 25M 57M 53M 7M 25M
otherInvestingActivites 69 000 136 000 83 000 130 000 -948 000 47 000
netCashUsedForInvestingActivites -10M -20M 8M 11M -7M 19M
debtRepayment -45 000 0 -77M -13 000 -12 000 -38M
commonStockIssued 7M 8M 9M 0 0 0
commonStockRepurchased 0 0 -32 000 0 0 0
dividendsPaid 0 0 -9M 0 0 0
otherFinancingActivites -1M -4M 9M -762 000 -5M -3M
netCashUsedProvidedByFinancingActivities 5M 3M -68M -775 000 -5M -41M
effectOfForexChangesOnCash 583 000 14M 70M 0 0 0
netChangeInCash 3M -9M -60M 44M 41M -1M
cashAtEndOfPeriod 23M 20M 28M 89M 45M 4M
cashAtBeginningOfPeriod 20M 28M 89M 45M 4M 5M
operatingCashFlow 8M 8M -82 000 34M 53M 20M
capitalExpenditure -51M -487 000 -203 000 -2M -1M -5M
freeCashFlow -43M 7M -285 000 32M 52M 15M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-27 12:00 ET
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-22 21:01 ET
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
2024-02-16 13:00 ET
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
2024-02-13 21:01 ET
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-02-01 22:00 ET
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 21:30 ET
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
2023-12-12 17:01 ET
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
2023-12-06 21:02 ET
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
2023-12-01 13:20 ET
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
2023-11-08 21:01 ET
Ligand Reports Third Quarter 2023 Financial Results
2023-11-01 12:00 ET
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
2023-10-25 20:01 ET
Ligand To Report Third Quarter 2023 Financial Results On November 8
2023-10-18 12:00 ET
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
2023-09-27 13:00 ET
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
2023-09-26 21:05 ET
Ligand Appoints Martine Zimmermann to its Board of Directors
2023-09-22 13:00 ET
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-09-21 13:20 ET
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
2023-09-18 21:17 ET
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
2023-09-02 02:02 ET
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-08-08 20:01 ET
Ligand Reports Second Quarter 2023 Financial Results
2023-07-27 17:30 ET
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
2023-07-25 20:30 ET
Ligand To Report Second Quarter 2023 Financial Results On August 8
2023-07-17 12:59 ET
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
2023-07-17 12:45 ET
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
2023-05-16 11:30 ET
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
2023-05-04 20:01 ET
Ligand Reports First Quarter 2023 Financial Results
2023-04-24 20:01 ET
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
2023-02-22 21:01 ET
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-17 23:30 ET
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
2023-02-16 13:00 ET
Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
2023-02-06 21:01 ET
Ligand to Report Fourth Quarter Financial Results on February 22
2023-01-06 13:05 ET
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
2022-12-13 13:30 ET
Ligand Provides Highlights from its Investor and Analyst Day Event
2022-12-05 12:00 ET
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
2022-11-16 13:00 ET
Ligand to Hold Investor and Analyst Day on December 13
2022-11-07 21:01 ET
Ligand Reports Third Quarter 2022 Financial Results
2022-11-01 20:01 ET
Ligand Announces Completion of OmniAb Spin-Off
2022-11-01 12:00 ET
Ligand Distribution of OmniAb Complete and Business Combination Closed
2022-10-26 22:00 ET
Ligand to Report Third Quarter Financial Results on November 7
2022-10-26 12:00 ET
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
2022-10-24 21:00 ET
OmniAb Business Combination Approved by APAC Shareholders
2022-10-03 20:30 ET
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-10-03 13:00 ET
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
2022-08-24 21:00 ET
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
2022-08-08 20:01 ET
Ligand Reports Second Quarter 2022 Financial Results
2022-08-01 23:22 ET
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-07-22 20:08 ET
Ligand to Report Second Quarter Financial Results on August 8
2022-06-29 20:01 ET
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
2022-05-04 20:01 ET
Ligand Reports First Quarter 2022 Financial Results
2022-04-19 20:01 ET
Ligand to Report First Quarter Financial Results on May 4
2022-04-08 20:50 ET
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-03-23 20:17 ET
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
2022-02-17 21:01 ET
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-09 14:01 ET
Ligand to Report Fourth Quarter Financial Results on February 17
2021-12-22 13:00 ET
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
2021-12-21 21:01 ET
Ligand and GSK Expand Global Collaboration and License Agreement
2021-11-09 21:02 ET
Ligand Reports Third Quarter 2021 Financial Results
2021-11-09 21:01 ET
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
2021-10-26 20:01 ET
Ligand to Report Third Quarter Financial Results on November 9, 2021
2021-10-21 13:00 ET
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
2021-08-30 23:00 ET
Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600
2021-08-30 20:01 ET
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
2021-08-16 18:53 ET
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
2021-07-29 20:01 ET
Ligand Reports Second Quarter 2021 Financial Results
2021-07-28 20:00 ET
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms
2021-07-21 13:00 ET
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
2021-07-19 12:00 ET
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
2021-07-16 13:00 ET
Ligand to Report Second Quarter Financial Results on July 29, 2021
2021-07-14 20:01 ET
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
2021-06-02 13:00 ET
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
2021-05-03 20:01 ET
Ligand Reports First Quarter 2021 Financial Results
2021-04-22 20:01 ET
Ligand to Report First Quarter Financial Results on May 3, 2021
2021-02-03 12:30 ET
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-02 16:59 ET
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
2021-01-20 13:30 ET
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
2021-01-13 13:30 ET
Ligand Receives Milestone Payment from Merck
2020-12-21 13:30 ET
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
2020-11-23 13:30 ET
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
2020-11-06 19:16 ET
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
2020-10-30 12:00 ET
Ligand Reports Third Quarter 2020 Financial Results
2020-10-23 12:30 ET
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
2020-10-20 18:05 ET
Ligand Provides Highlights from Today’s Investor Day Event
2020-10-19 20:02 ET
Ligand’s Third Quarter Financial Results to be Reported October 30th
2020-10-12 13:00 ET
Ligand to Divest Vernalis Research Operations
2020-10-12 10:24 ET
HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery
2020-10-02 12:00 ET
Ligand to Host Virtual Investor Day on October 20th
2020-10-01 12:24 ET
Ligand Completes Acquisition of Pfenex Inc.
2020-09-30 12:00 ET
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
2020-09-23 12:00 ET
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
2020-09-10 12:00 ET
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
2020-09-01 20:02 ET
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
2020-08-31 13:00 ET
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
2020-08-25 20:15 ET
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
2020-08-24 12:30 ET
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma
2020-08-10 21:36 ET
Ligand to Acquire Pfenex Inc.
2020-08-07 12:30 ET
CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application
2020-08-03 11:30 ET
Ligand Reports Second Quarter 2020 Financial Results
2020-07-16 20:28 ET
Ligand’s Second Quarter Financial Results to be Reported August 3rd
2020-07-13 11:51 ET
Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies
2020-06-15 12:30 ET
Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
2020-06-01 20:53 ET
Ligand CEO Issues Letter to Captisol Customers
2020-05-29 12:00 ET
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
2020-05-28 20:22 ET
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
2020-05-06 20:01 ET
Ligand Reports First Quarter 2020 Financial Results
2020-04-22 12:30 ET
Ligand’s First Quarter Financial Results to be Reported May 6th
2020-04-06 11:00 ET
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
2020-04-02 20:02 ET
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
2020-03-10 12:00 ET
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
2020-03-02 13:00 ET
Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
2020-02-27 13:00 ET
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
2020-02-11 21:14 ET
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
2020-02-06 21:01 ET
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-03 13:30 ET
Ligand's Technologies Support and Enable Potential Coronavirus Treatments
2020-01-13 21:02 ET
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
2020-01-09 19:47 ET
Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
2019-12-23 13:30 ET
Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
2019-12-02 13:30 ET
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
2019-11-12 13:30 ET
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
2019-11-08 13:30 ET
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
2019-11-07 13:30 ET
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
2019-11-05 21:01 ET
Ligand Reports Third Quarter 2019 Financial Results
2019-10-22 20:01 ET
Ligand to Report Third Quarter 2019 Results on November 5th
2019-10-15 13:00 ET
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
2019-07-30 15:30 ET
Lemelson Capital Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Calls on US Attorney to Investigate
2019-07-16 15:19 ET
Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP
2019-07-08 12:30 ET
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
2019-03-11 10:00 ET
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
2019-03-04 15:00 ET
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
2019-02-01 12:40 ET
Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties — Fundamental Analysis, Key Performance Indications

SEC forms

Show financial reports only

SEC form 10
2024-02-29 00:00 ET
Ligand Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:24 ET
Ligand Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:24 ET
Ligand Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-08 16:08 ET
Ligand Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-09 16:03 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-08 16:02 ET
Ligand Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-09 17:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-13 08:02 ET
Ligand Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 16:03 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-22 16:05 ET
Ligand Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 6
2022-12-27 18:31 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:31 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:30 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:28 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-14 16:07 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-05 07:03 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-08 16:03 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-07 20:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-07 20:23 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-07 16:04 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-04 16:08 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-03 21:10 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-03 21:05 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 09:18 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-30 17:13 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:13 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-02 16:10 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-29 17:17 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-21 06:19 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-10 19:26 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-09 16:08 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 16:03 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-22 16:11 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-24 09:08 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-23 17:25 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 17:27 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-17 16:03 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-27 16:02 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-14 16:23 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-09 17:06 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 16:06 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-16 16:15 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-02 19:56 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:04 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-21 09:05 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-14 16:08 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-04 19:48 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:07 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-03 16:11 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-03 00:00 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:09 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-24 17:03 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:45 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-28 16:42 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-21 08:39 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-16 16:19 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-10 16:13 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-02 20:05 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-23 08:32 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-12 16:16 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 16:11 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 17:01 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 16:07 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 08:03 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-20 10:52 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-13 08:44 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-01 08:42 ET
Ligand Pharmaceuticals published news for 2020 q3